Silence Therapeutics plc
SLNCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $43 | $25 | $18 | $12 |
| % Growth | 70.5% | 45% | 41% | – |
| Cost of Goods Sold | $12 | $10 | $11 | $7 |
| Gross Profit | $31 | $15 | $8 | $5 |
| % Margin | 72.7% | 59.3% | 46.8% | 39.9% |
| R&D Expenses | $68 | $44 | $36 | $31 |
| G&A Expenses | $27 | $26 | $26 | $20 |
| SG&A Expenses | $27 | $26 | $26 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$10 | -$11 | $0 |
| Operating Expenses | $95 | $65 | $55 | $51 |
| Operating Income | -$63 | -$50 | -$49 | -$46 |
| % Margin | -146.4% | -195.5% | -277.7% | -369% |
| Other Income/Exp. Net | $19 | -$1 | $1 | -$0 |
| Pre-Tax Income | -$44 | -$50 | -$47 | -$46 |
| Tax Expense | $1 | -$7 | -$7 | -$6 |
| Net Income | -$45 | -$43 | -$40 | -$39 |
| % Margin | -104.7% | -170.5% | -231.4% | -317.4% |
| EPS | -0.33 | -0.49 | -0.52 | -0.44 |
| % Growth | 32.7% | 5.8% | -18.2% | – |
| EPS Diluted | -0.33 | -0.49 | -0.52 | -0.44 |
| Weighted Avg Shares Out | 139 | 111 | 97 | 89 |
| Weighted Avg Shares Out Dil | 139 | 111 | 97 | 89 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | -$49 | -$50 | -$51 | -$45 |
| % Margin | -113.2% | -196.2% | -289.3% | -365.9% |